Department of Nutrition, School of Public Health, Sun Yat-Sen University (Northern Campus), Guangzhou, China,
Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, China,
Ann Nutr Metab. 2022;78(1):21-32. doi: 10.1159/000520368. Epub 2021 Nov 23.
Adipokine alterations contribute to the development and remission of nonalcoholic fatty-liver disease (NAFLD). Adipsin is one of the most abundant adipokines and is almost exclusively produced by adipocytes. However, data on adipsin in human NAFLD are limited and controversial. We performed this study to investigate the association between adipsin and the remission of NAFLD in middle-aged and elderly Chinese adults.
Whether adipsin is associated with the remission of NAFLD in a 3-year community-based prospective cohort study was investigated. Baseline levels of adipsin were measured in serum samples collected from 908 NAFLD participants. NAFLD was diagnosed using abdominal ultrasonography. Logistic regression analysis and a multiple stepwise logistic regression model including different variables were conducted to evaluate the association between serum adipsin levels and the remission of NAFLD.
During a mean follow-up of 3.14 ± 0.36 years, 247 (27.20%) participants with NAFLD at baseline were in remission. At baseline, serum adipsin concentration was positively correlated with body mass index (r: 0.39, p < 0.001), insulin (r: 0.31, p < 0.001), and homeostasis model assessment of insulin resistance (r: 0.31, p < 0.001) and was inversely associated with NAFLD remission with a fully adjusted odds ratio (OR) of 0.28 (0.16-0.48) (p trend < 0.001). In a multiple stepwise logistic regression model, circulating adipsin independently predicted NAFLD remission (OR: 0.284, 95% confidence interval [CI]: 0.172-0.471, p for trend <0.001). The area under the receiver operating characteristic curve was 0.751 (95% CI: 0.717-0.785) (p < 0.001) for the prediction model of NAFLD remission.
We provide evidence for an association between serum adipsin levels and the remission of NAFLD in a community-based prospective cohort study. Serum adipsin can be a potential biomarker for predicting NAFLD remission.
脂肪因子的改变有助于非酒精性脂肪性肝病（NAFLD）的发生和缓解。 adiposin 是最丰富的脂肪因子之一，几乎完全由脂肪细胞产生。然而，关于人类 NAFLD 中 adiposin 的数据有限且存在争议。我们进行了这项研究，以调查 adiposin 与中国中老年人群 NAFLD 缓解之间的关系。
在一项基于社区的前瞻性队列研究中，研究了 adiposin 是否与 NAFLD 的缓解有关。从 908 名 NAFLD 患者的血清样本中测量 adiposin 的基线水平。使用腹部超声诊断 NAFLD。采用逻辑回归分析和包含不同变量的多步逻辑回归模型来评估血清 adiposin 水平与 NAFLD 缓解之间的关系。
在平均 3.14±0.36 年的随访期间，基线时有 247（27.20%）名 NAFLD 患者得到缓解。基线时，血清 adiposin 浓度与体重指数（r：0.39，p<0.001）、胰岛素（r：0.31，p<0.001）和稳态模型评估的胰岛素抵抗（r：0.31，p<0.001）呈正相关，与完全调整后的优势比（OR）为 0.28（0.16-0.48）（p 趋势<0.001）呈负相关。在多步逻辑回归模型中，循环 adiposin 独立预测 NAFLD 缓解（OR：0.284，95%置信区间 [CI]：0.172-0.471，p 趋势<0.001）。NAFLD 缓解预测模型的受试者工作特征曲线下面积为 0.751（95%CI：0.717-0.785）（p<0.001）。
我们在一项基于社区的前瞻性队列研究中提供了血清 adiposin 水平与 NAFLD 缓解之间存在关联的证据。血清 adiposin 可能是预测 NAFLD 缓解的潜在生物标志物。
